{
  "id": 19149418,
  "title": "Faeth reports phase 2 trial results for endometrial cancer drug",
  "url": "https://urgent.news/2026/11/09/faeth-reports-phase-2-trial-results-for-endometrial-cancer-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-09T12:24:40.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/faeth-reports-phase-2-trial-results-for-endometrial-cancer-drug-93CH-5011681"
  },
  "original_language": "en",
  "account": "Austin, Texas - Faeth Therapeutics (FTH) has released results from a phase 2 trial investigating PIKTOR, a potential drug combination for advanced endometrioid endometrial cancer. The trial, conducted in collaboration with The GOG Foundation, enrolled 42 patients with the specific cancer type and a key genetic mutation. Of these, 12 out of 36 efficacy-evaluable patients achieved confirmed objective responses, indicating a 33% overall response rate. Among patients with the PIK3CA mutation, the response rate was even higher at 44%, or 7 of 16 patients. The disease control rate achieved 83% success. The estimated median progression-free survival was 7.4 months, with 62% of patients surviving without progression for at least 6 months. At the data cutoff, 16 patients continued treatment. Most patients (98%) had undergone prior taxane-based chemotherapy and immunotherapy. Sixty percent had distant metastases, and 48% had diabetes or pre-diabetes. Approximately 5% of patients stopped treatment due to treatment-related side effects, with 12% experiencing hyperglycemia and 2% experiencing grade 3 stomach issues. The company plans to move forward with a phase 3 trial, pending regulatory approval.",
  "summary": null,
  "key_points": [
    "Faeth Therapeutics reports phase 2 trial results for PIKTOR drug.",
    "33% overall response rate in 36 efficacy-evaluable patients.",
    "44% response rate among patients with PIK3CA mutation."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}